RPTX Stock Overview
A clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Repare Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.48 |
| 52 Week High | US$13.85 |
| 52 Week Low | US$2.98 |
| Beta | 0.70 |
| 1 Month Change | 10.48% |
| 3 Month Change | -44.59% |
| 1 Year Change | -64.71% |
| 3 Year Change | -89.68% |
| 5 Year Change | n/a |
| Change since IPO | -88.70% |
Recent News & Updates
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01
Recent updates
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19Shareholder Returns
| RPTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | 2.2% | 1.7% |
| 1Y | -64.7% | 5.8% | 26.0% |
Return vs Industry: RPTX underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: RPTX underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| RPTX volatility | |
|---|---|
| RPTX Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RPTX's share price has been volatile over the past 3 months.
Volatility Over Time: RPTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 179 | Lloyd Segal | www.reparerx.com |
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Repare Therapeutics Inc. Fundamentals Summary
| RPTX fundamental statistics | |
|---|---|
| Market cap | US$150.68m |
| Earnings (TTM) | -US$45.69m |
| Revenue (TTM) | US$97.86m |
1.5x
P/S Ratio-3.2x
P/E RatioIs RPTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPTX income statement (TTM) | |
|---|---|
| Revenue | US$97.86m |
| Cost of Revenue | US$131.20m |
| Gross Profit | -US$33.34m |
| Other Expenses | US$12.35m |
| Earnings | -US$45.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -34.07% |
| Net Profit Margin | -46.69% |
| Debt/Equity Ratio | 0% |
How did RPTX perform over the long term?
See historical performance and comparison